Bryce Point Capital LLC Makes New Investment in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Bryce Point Capital LLC purchased a new stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) in the fourth quarter, Holdings Channel reports. The institutional investor purchased 54,358 shares of the biopharmaceutical company’s stock, valued at approximately $1,134,000.

Several other hedge funds also recently modified their holdings of the company. Steward Partners Investment Advisory LLC bought a new position in Catalyst Pharmaceuticals in the fourth quarter valued at about $27,000. Farther Finance Advisors LLC increased its stake in shares of Catalyst Pharmaceuticals by 125.1% in the fourth quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company’s stock valued at $56,000 after buying an additional 1,495 shares during the period. Wilmington Savings Fund Society FSB bought a new position in Catalyst Pharmaceuticals in the 4th quarter valued at approximately $65,000. KBC Group NV grew its holdings in Catalyst Pharmaceuticals by 48.8% during the 4th quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company’s stock worth $98,000 after acquiring an additional 1,542 shares during the last quarter. Finally, Thurston Springer Miller Herd & Titak Inc. acquired a new position in Catalyst Pharmaceuticals in the 4th quarter valued at approximately $134,000. Institutional investors and hedge funds own 79.22% of the company’s stock.

Insider Activity

In other Catalyst Pharmaceuticals news, insider Brian Elsbernd sold 62,975 shares of the firm’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $22.98, for a total value of $1,447,165.50. Following the completion of the sale, the insider now owns 188,564 shares of the company’s stock, valued at approximately $4,333,200.72. This trade represents a 25.04 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Gary Ingenito sold 44,904 shares of the business’s stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $22.09, for a total value of $991,929.36. Following the sale, the insider now owns 68,873 shares of the company’s stock, valued at approximately $1,521,404.57. This represents a 39.47 % decrease in their position. The disclosure for this sale can be found here. 11.00% of the stock is currently owned by company insiders.

Analyst Ratings Changes

CPRX has been the topic of a number of recent research reports. Stephens reiterated an “overweight” rating and set a $33.00 price target on shares of Catalyst Pharmaceuticals in a report on Thursday, February 27th. Robert W. Baird increased their price target on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an “outperform” rating in a research note on Monday, March 3rd. HC Wainwright reiterated a “buy” rating and issued a $35.00 target price on shares of Catalyst Pharmaceuticals in a report on Friday, February 28th. StockNews.com upgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, February 28th. Finally, Bank of America restated a “buy” rating and issued a $30.00 price target on shares of Catalyst Pharmaceuticals in a research report on Thursday, January 9th. Seven investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $32.29.

Catalyst Pharmaceuticals Trading Up 2.3 %

CPRX opened at $24.46 on Thursday. The company has a fifty day moving average price of $22.74 and a two-hundred day moving average price of $21.90. Catalyst Pharmaceuticals, Inc. has a 1-year low of $14.47 and a 1-year high of $26.16. The company has a market cap of $2.97 billion, a P/E ratio of 20.73, a price-to-earnings-growth ratio of 3.31 and a beta of 0.79.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.